American Association for Cancer Research
Browse

sorry, we can't preview this file

crc-21-0137-s02.pptx (58.74 kB)

Figure S2 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

Download (58.74 kB)
figure
posted on 2023-04-04, 01:46 authored by Richard Kurupi, Konstantinos V. Floros, Sheeba Jacob, Ayesha T. Chawla, Jinyang Cai, Bin Hu, Madhavi Puchalapalli, Colin M. Coon, Rishabh Khatri, Giovanna Stein Crowther, Regina K. Egan, Ellen Murchie, Patricia Greninger, Krista M. Dalton, Maninderjit S. Ghotra, Sosipatros A. Boikos, Jennifer E. Koblinski, Hisashi Harada, Yue Sun, Iain M. Morgan, Devraj Basu, Mikhail G. Dozmorov, Cyril H. Benes, Anthony C. Faber

HNSCC tumor cell lines are effective to SHP099 through dual PI3K and MEK inhibition

Funding

HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

This work identifies a novel role of SHP2 inhibitor by dual downregulation of PI3K and MEK pathways, through loss of GAB1 activation and disruption of GAB1 complexes in low-epiregulin HNSCC.